後天性免疫不全症候群（AIDS）の世界市場レポート 2025年

後天性免疫不全症候群（AIDS）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.3％で415億7,000万米ドルに成長します。予測期間の成長は、長時間作用型注射療法に対する需要の高まり、曝露前予防薬（PrEP）の採用拡大、HIV治療研究への投資の増加、HIVケアのための遠隔医療サービスの拡大、個別化医療への注目の高まり、HIVの早期診断に対する意識の高まりなどに起因すると考えられます。この期間の主な動向としては、単剤レジメンへの移行、注射・埋め込み型HIV治療への嗜好の高まり、HIV管理におけるデジタルヘルスソリューションへの需要の高まり、機能的HIV治療戦略への関心の高まり、創薬における人工知能の役割の拡大などが挙げられます。

HIV感染率の増加は、後天性免疫不全症候群（AIDS）市場の成長を促進すると予想されます。HIV感染症とは、ヒト免疫不全ウイルスによって引き起こされる症状を指し、免疫系を弱めることで感染症や病気と闘うことが難しくなります。HIV感染率の上昇は、感染者との無防備な性交渉、注射針の共有、汚染された血液製剤の摂取、複数の性的パートナーの存在、免疫力の低下や既存の性感染症などの要因に起因しています。エイズの管理は、早期診断の促進、効果的な抗レトロウイルス療法へのアクセスの改善、予防戦略の強化、ウイルスの蔓延をよりよく制御するためのヘルスケアシステムの強化によって、HIV患者を支援します。例えば、2024年11月に欧州疾病予防管理センター（ECDC）が報告した2023年の新規HIV感染者数は、域内53ヵ国中47ヵ国で11万2,883人であり、このうち2万4,731人が欧州連合/欧州経済領域（EU/EEA）で発生しています。これは、HIV診断の粗率が前年比で2.4%増加したことを意味し、HIV感染の有病率が高まっていることを示しており、AIDS市場の拡大に寄与しています。

エイズ市場で事業を展開する企業は、患者の服薬アドヒアランスを向上させ、投与回数を減らし、毎日の経口抗レトロウイルス治療に代わるより便利な治療法を提供するため、長時間作用型注射剤のような革新的な治療法の開発に注力しています。これらの注射剤は、有効成分が時間をかけてゆっくりと放出されるように設計されているため、従来の経口薬に比べて投与回数を減らすことができます。例えば、2025年1月、英国の製薬会社GSK plc.は、欧州委員会からボカブリア（カボテグラビル）とレカンビス（リルピビリン）からなる長時間作用型注射剤の承認を取得しました。この治療薬は、HIVに感染している12歳以上の青少年を対象に承認されており、通常、治療計画に応じて1～2カ月ごとに筋肉内注射で投与されます。この長時間作用型製剤は、毎日の錠剤レジメンに苦労している青少年の服薬アドヒアランス率を向上させることができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界後天性免疫不全症候群（AIDS） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の後天性免疫不全症候群（AIDS）市場：成長率分析
• 世界の後天性免疫不全症候群（AIDS）市場の実績：規模と成長, 2019-2024
• 世界の後天性免疫不全症候群（AIDS）市場の予測：規模と成長, 2024-2029, 2034F
• 世界後天性免疫不全症候群（AIDS）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の後天性免疫不全症候群（AIDS）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒト免疫不全ウイルス1型
• ヒト免疫不全ウイルス2
• 世界の後天性免疫不全症候群（AIDS）市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヌクレオシド類似体逆転写酵素阻害剤
• 非ヌクレオシド系逆転写酵素阻害剤
• 融合阻害剤
• CCR5拮抗薬および接着後阻害剤
• プロテアーゼ阻害剤
• インテグラーゼ阻害剤
• 曝露前予防と曝露後予防
• 世界の後天性免疫不全症候群（AIDS）市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の後天性免疫不全症候群（AIDS）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の用途
• 世界の後天性免疫不全症候群（AIDS）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オフライン
• オンライン
• 世界の後天性免疫不全症候群（AIDS）市場ヒト免疫不全ウイルス1型（HIV-1）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗レトロウイルス療法（ART）
• 曝露前予防（PrEP）
• 曝露後予防（PEP）
• HIV-1診断検査
• HIV-1ワクチン開発
• HIV-1日和見感染症の管理
• 世界の後天性免疫不全症候群（AIDS）市場ヒト免疫不全ウイルス2型（HIV-2）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• HIV-2に対する抗レトロウイルス療法（ART）
• HIV-2診断検査
• HIV-2の監視と疫学
• HIV-2ワクチン調査
• HIV-2の重複感染の管理

第7章 地域別・国別分析

• 世界の後天性免疫不全症候群（AIDS）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の後天性免疫不全症候群（AIDS）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 後天性免疫不全症候群（AIDS）市場：競合情勢
• 後天性免疫不全症候群（AIDS）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• Abbott
• GSK plc
• Takeda Pharmaceuticals
• Gilead Sciences
• Viatris Inc.
• Teva Pharmaceuticals
• Aurobindo Pharma
• Cipla Ltd
• Shionogi and Co.
• Dr. Reddy's Laboratories
• Lupin
• Hetero Drugs Limited
• Glenmark Pharmaceuticals Limited
• ViiV Healthcare

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 後天性免疫不全症候群（AIDS）市場2029：新たな機会を提供する国
• 後天性免疫不全症候群（AIDS）市場2029：新たな機会を提供するセグメント
• 後天性免疫不全症候群（AIDS）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acquired immunodeficiency syndrome (AIDS) is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV), which progressively weakens the immune system by attacking and destroying CD4 T cells. This leaves the body susceptible to opportunistic infections, severe illnesses, and certain cancers unless effective antiretroviral treatment (ART) is administered. AIDS management involves a combination of ART, regular monitoring of immune function, prevention of opportunistic infections, and comprehensive healthcare support to enhance patient outcomes and quality of life.

The main types of acquired immunodeficiency syndrome (AIDS) include human immunodeficiency virus 1 (HIV-1) and human immunodeficiency virus 2 (HIV-2). HIV-1 is a retrovirus that primarily infects CD4+ T cells, leading to progressive immunodeficiency and, if untreated, the development of AIDS. Drugs used in treating AIDS include nucleoside-analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, protease inhibitors, integrase inhibitors, and pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). These drugs are administered orally or parenterally and are used in various settings, including hospital pharmacies, retail pharmacies, and others, with distribution via both offline and online channels.

The acquired immunodeficiency syndrome (AIDS) market research report is one of a series of new reports from The Business Research Company that provides acquired immunodeficiency syndrome (AIDS) market statistics, including acquired immunodeficiency syndrome (AIDS) industry global market size, regional shares, competitors with a acquired immunodeficiency syndrome (AIDS) market share, detailed acquired immunodeficiency syndrome (AIDS) market segments, market trends and opportunities, and any further data you may need to thrive in the acquired immunodeficiency syndrome (AIDS) industry. This acquired immunodeficiency syndrome (AIDS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acquired immunodeficiency syndrome (AIDS) market size has grown strongly in recent years. It will grow from $32.09 billion in 2024 to $33.85 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to the rising rates of HIV infections, increased government funding for HIV treatment, the expansion of global awareness programs, improvements in diagnostic capabilities, and growing support from non-governmental organizations.

The acquired immunodeficiency syndrome (AIDS) market size is expected to see strong growth in the next few years. It will grow to $41.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The projected growth in the forecast period can be attributed to the rising demand for long-acting injectable therapies, increasing adoption of pre-exposure prophylaxis (PrEP), growing investment in HIV cure research, the expansion of telemedicine services for HIV care, a heightened focus on personalized medicine, and increased awareness about early HIV diagnosis. Key trends during this period include a shift toward single-tablet regimens, a growing preference for injectable and implantable HIV treatments, a rising demand for digital health solutions in HIV management, increased interest in functional HIV cure strategies, and the expanding role of artificial intelligence in drug discovery.

The increasing rates of HIV infections are expected to drive the growth of the acquired immunodeficiency syndrome (AIDS) market. HIV infections refer to the condition caused by the human immunodeficiency virus, which weakens the immune system, making it harder for the body to fight infections and diseases. The rising rates of HIV infections can be attributed to factors such as unprotected sexual intercourse with an infected individual, sharing needles, receiving contaminated blood products, having multiple sexual partners, and a weakened immune system or existing sexually transmitted infections. Management of AIDS helps patients with HIV by promoting early diagnosis, improving access to effective antiretroviral therapies, enhancing prevention strategies, and strengthening healthcare systems to better control the spread of the virus. For example, in November 2024, the European Centre for Disease Prevention and Control (ECDC) reported 112,883 new HIV diagnoses in 2023 across 47 out of 53 countries in the region, with 24,731 of these cases occurring in the European Union/European Economic Area (EU/EEA). This marks a 2.4% increase in the crude rate of HIV diagnoses compared to the previous year, indicating the growing prevalence of HIV infections and contributing to the expansion of the AIDS market.

Companies operating in the AIDS market are focusing on the development of innovative therapies such as long-acting injectables to improve patient adherence, reduce dosing frequency, and offer a more convenient alternative to daily oral antiretroviral treatments. These injectables are designed to release their active ingredients slowly over time, which allows for less frequent dosing compared to traditional oral medications. For example, in January 2025, GSK plc., a UK-based pharmaceutical company, received approval from the European Commission for a long-acting injectable treatment consisting of Vocabria (cabotegravir) and Rekambys (rilpivirine). This treatment, approved for adolescents aged 12 years and older living with HIV, is administered through an intramuscular injection, typically every one or two months, depending on the treatment plan. This long-acting formulation can improve adherence rates among adolescents who may struggle with daily pill regimens.

In November 2024, Gilead Sciences Inc., a U.S.-based biopharmaceutical company, acquired investigational assets for the HTI therapeutic HIV vaccine from AELIX Therapeutics. Through this acquisition, Gilead aims to enhance its HIV treatment portfolio by advancing research into functional HIV cures and potentially reducing the reliance on lifelong antiretroviral therapy. AELIX Therapeutics, based in Spain, focuses on developing treatments and vaccines for AIDS.

Major players in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy's Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare.

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acquired immunodeficiency syndrome (AIDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acquired immunodeficiency syndrome (AIDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acquired immunodeficiency syndrome (AIDS) market consists of sales of products such as long-acting injectable antiretrovirals, broadly neutralizing antibodies (bNAbs), therapeutic HIV vaccines, latency-reversing agents, capsid inhibitors, attachment inhibitors, maturation inhibitors, and pharmacokinetic enhancers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acquired Immunodeficiency Syndrome (AIDS) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acquired immunodeficiency syndrome (aids) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acquired immunodeficiency syndrome (aids) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acquired immunodeficiency syndrome (aids) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Human Immunodeficiency Virus 1; Human Immunodeficiency Virus 2
• 2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors; Non-Nucleoside Reverse Transcriptase Inhibitors; Fusion Inhibitors; CCR5 Anatagonists And Post-Attachment Inhibitors; Protease Inhibitors; Integrase Inhibitors; Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Application: Hospital Pharmacy; Retail Pharmacy; Other Applications
• 5) By Distribution Channel: Offline; Online
• Subsegments:
• 1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART); Pre-Exposure Prophylaxis (PrEP); Post-Exposure Prophylaxis (PEP); HIV-1 Diagnostic Tests; HIV-1 Vaccine Development; HIV-1 Opportunistic Infection Management
• 2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2; HIV-2 Diagnostic Tests; HIV-2 Surveillance And Epidemiology; HIV-2 Vaccine Research; Management Of HIV-2 Co-Infections
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acquired Immunodeficiency Syndrome (AIDS) Market Characteristics

3. Acquired Immunodeficiency Syndrome (AIDS) Market Trends And Strategies

4. Acquired Immunodeficiency Syndrome (AIDS) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acquired Immunodeficiency Syndrome (AIDS) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acquired Immunodeficiency Syndrome (AIDS) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acquired Immunodeficiency Syndrome (AIDS) Market Growth Rate Analysis
• 5.4. Global Acquired Immunodeficiency Syndrome (AIDS) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acquired Immunodeficiency Syndrome (AIDS) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acquired Immunodeficiency Syndrome (AIDS) Total Addressable Market (TAM)

6. Acquired Immunodeficiency Syndrome (AIDS) Market Segmentation

• 6.1. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Immunodeficiency Virus 1
• Human Immunodeficiency Virus 2
• 6.2. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside-Analog Reverse Transcriptase Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Fusion Inhibitors
• CCR5 Anatagonists and Post-Attachment Inhibitors
• Protease Inhibitors
• Integrase Inhibitors
• Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
• 6.3. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Other Applications
• 6.5. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Offline
• Online
• 6.6. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Sub-Segmentation Of Human Immunodeficiency Virus 1 (HIV-1), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiretroviral Therapy (ART)
• Pre-Exposure Prophylaxis (PrEP)
• Post-Exposure Prophylaxis (PEP)
• HIV-1 Diagnostic Tests
• HIV-1 Vaccine Development
• HIV-1 Opportunistic Infection Management
• 6.7. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Sub-Segmentation Of Human Immunodeficiency Virus 2 (HIV-2), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiretroviral Therapy (ART) For HIV-2
• HIV-2 Diagnostic Tests
• HIV-2 Surveillance And Epidemiology
• HIV-2 Vaccine Research
• Management Of HIV-2 Co-Infections

7. Acquired Immunodeficiency Syndrome (AIDS) Market Regional And Country Analysis

• 7.1. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acquired Immunodeficiency Syndrome (AIDS) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market

• 8.1. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acquired Immunodeficiency Syndrome (AIDS) Market

• 9.1. China Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 9.2. China Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acquired Immunodeficiency Syndrome (AIDS) Market

• 10.1. India Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acquired Immunodeficiency Syndrome (AIDS) Market

• 11.1. Japan Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 11.2. Japan Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acquired Immunodeficiency Syndrome (AIDS) Market

• 12.1. Australia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acquired Immunodeficiency Syndrome (AIDS) Market

• 13.1. Indonesia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market

• 14.1. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 14.2. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market

• 15.1. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 15.2. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acquired Immunodeficiency Syndrome (AIDS) Market

• 16.1. UK Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acquired Immunodeficiency Syndrome (AIDS) Market

• 17.1. Germany Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acquired Immunodeficiency Syndrome (AIDS) Market

• 18.1. France Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acquired Immunodeficiency Syndrome (AIDS) Market

• 19.1. Italy Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acquired Immunodeficiency Syndrome (AIDS) Market

• 20.1. Spain Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market

• 21.1. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 21.2. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acquired Immunodeficiency Syndrome (AIDS) Market

• 22.1. Russia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acquired Immunodeficiency Syndrome (AIDS) Market

• 23.1. North America Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 23.2. North America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acquired Immunodeficiency Syndrome (AIDS) Market

• 24.1. USA Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 24.2. USA Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acquired Immunodeficiency Syndrome (AIDS) Market

• 25.1. Canada Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 25.2. Canada Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acquired Immunodeficiency Syndrome (AIDS) Market

• 26.1. South America Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 26.2. South America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acquired Immunodeficiency Syndrome (AIDS) Market

• 27.1. Brazil Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market

• 28.1. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 28.2. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acquired Immunodeficiency Syndrome (AIDS) Market

• 29.1. Africa Acquired Immunodeficiency Syndrome (AIDS) Market Overview
• 29.2. Africa Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acquired Immunodeficiency Syndrome (AIDS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acquired Immunodeficiency Syndrome (AIDS) Market Competitive Landscape And Company Profiles

• 30.1. Acquired Immunodeficiency Syndrome (AIDS) Market Competitive Landscape
• 30.2. Acquired Immunodeficiency Syndrome (AIDS) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Acquired Immunodeficiency Syndrome (AIDS) Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Abbott
• 31.3. GSK plc
• 31.4. Takeda Pharmaceuticals
• 31.5. Gilead Sciences
• 31.6. Viatris Inc.
• 31.7. Teva Pharmaceuticals
• 31.8. Aurobindo Pharma
• 31.9. Cipla Ltd
• 31.10. Shionogi and Co.
• 31.11. Dr. Reddy's Laboratories
• 31.12. Lupin
• 31.13. Hetero Drugs Limited
• 31.14. Glenmark Pharmaceuticals Limited
• 31.15. ViiV Healthcare

32. Global Acquired Immunodeficiency Syndrome (AIDS) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acquired Immunodeficiency Syndrome (AIDS) Market

34. Recent Developments In The Acquired Immunodeficiency Syndrome (AIDS) Market

35. Acquired Immunodeficiency Syndrome (AIDS) Market High Potential Countries, Segments and Strategies

• 35.1 Acquired Immunodeficiency Syndrome (AIDS) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acquired Immunodeficiency Syndrome (AIDS) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acquired Immunodeficiency Syndrome (AIDS) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer